Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 668-677

  Currie, Craig J ^a,b   Poole, Chris D ^a,b   Evans, Marc ^c   Peters, John R ^c   Christopher Ll Morgan, ^a,b  

^a Department of Primary Care and Public Health Pharmatelligence ^*  (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84873656406     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3042     Document Type: Article

References (38)

1. National Institute for Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. 2008. http://guidance.nice.org.uk/CG66. Accessed August 8, 2012.
2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222.
3. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010;53:2079-2085.
4. European Medicines Agency. 2010 European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/07/ WC500094981.pdf. Accessed August 5, 2012.
5. FDA. 2010 Drug Safety Communication: Ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. Available from URL http://www.fda.gov/Drugs/Drugsafety/ucm226214.htm. Accessed August 5, 2012.
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30.
7. Currie CJ, Peters JR, Evans M. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. Diabet Med. 2010;27:744-752.
8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2011;34:S11-S61.
9. Rensing KL, Reuwer AQ, Arsenault BJ, et al. Reducing cardiovascular disease risk in diabetic persons with established macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab. 2011;13:1073-1087.
10. Nandish S, Bailon O, Wyatt J, Smith J, Stevens A, Lujan M, Chilton R. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep. 2011;13:123-128.
11. Lebovitz HE. Insulin: potential negative consequences of early routine use in persons with type 2 diabetes. Diabetes Care. 2011; 34(suppl 2):s225-s230.
12. Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14:1-4.
13. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010;12:47-53.
14. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481-489.
15. Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011;34:77-83.
16. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Safe. 2008;17:753-759.
17. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in persons with advanced heart failure. Am Heart J. 2005;149:168-174.
18. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia. 2010;53:1552-1561.
19. Antoniades C, Tousoulis D, Marinou K, et al. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin Cardiol. 2007;30:295-300.
20. Angiolillo DJ, Bernardo E, Ramírez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298-304.
21. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010;53:1631-1637.
22. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52: 1766-1777.
23. Medicines and Healthcare Products Regulatory Agency. The Clinical Practice Research Datalink (CPRD). 2012. http://www.cprd.com. Accessed August 5, 2012.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
25. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction-long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
26. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L, for the DIGAMI 2 Investigators. Prognostic implications of glucoselowering treatment in persons with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia. 2011;54:1308-1317.
27. Liebl A, Jones S, Benroubi, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin. 2011;27:887-895.
28. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose-lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
29. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. NEngl J Med. 2012;367:319-328.
30. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008;109:389-395.
31. Nkondi Mbadi AN, Longo-Mbenza B, Mvitu Muaka M, Mbungu FS, Lemogoum D. Relationship between pulse pressure, visual impairment and severity of diabetic retinopathy in sub-Saharan Africa. Mali Med. 2009;24:17-21.
32. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. Anovel mechanism for insulin resistance. J Clin Invest. 1990;85:1844-1852.
33. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-2515.
34. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension. 1999;33:1118-1122.
35. Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011;58:839-846.
36. Vadde Ramakrishna V, Jailkhani R. Oxidative stress in non-insulindependent diabetes mellitus (NIDDM) patients. Acta Diabetologica. 2008;45:41-46.
37. ISPOR. 2012 Good Outcomes Research Practices Index. http://www.ispor.org/ workpaper/practices-index.asp. Accessed August 5, 2012.
38. Khan Nada F, Harrison Sian E, Rose Peter W. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128-e136.